Poolbeg Pharma CEO Jeremy Skillington and Executive Chairman Cathal Friel joined Proactive to discuss the clinical stage infectious disease pharmaceutical company's recent developments, including beginning to trade its shares on the OTCQB platform in the US. Skillington and Friel say it expects to update the market regularly with its clinical development updates of its POLB 001 program for severe influenza, and to drive value for investors.
Poolbeg Pharma Plc beings trading on the OTCQB platform to attract more US investors
